ASCO 2024: The Role of ctDNA in the TheraP Trial - LuPSMA vs Cabazitaxel in CRPC

By The Uromigos - Last Updated: July 10, 2024

Dr. Alex Wyatt from Vancouver Prostate Centre describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial.

Post Tags:Uromigos-ASCO
Advertisement

Related Podcasts

Episode 368: Radiomics in RCC - Live From IKCS
Uromigos-Kidney Cancer
Episode 367: Abiraterone vs AR Inhibitors (Fanta vs Coke) in Prostate Cancer
Uromigos-Prostate Cancer
Episode 366: ARPIs in Prostate Cancer - Are They Different?
Uromigos-Prostate Cancer
Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC)
Uromigos-Prostate Cancer
Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer
Uromigos-Prostate Cancer
Advertisement
Advertisement

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    About Us

    Contributors and Partners

    Editorial Policy

    Advertising

    Connect

    eNewsletters

    Calendar

    Contact Us

    Contribute

    Our Network

    MashupMD

    Cancer Nursing Today

    Urban Health Today

    Blood Cancers Today

    DocWire News

    © 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy